Senju Pharmaceutical Co., Ltd.

Rie Nagao

Kazumi Ogata

Takahiro Sakaue

Shinya Ogino

Sachiko Matsuura

Noriko Saito

Yasuko Umegaki

This invention provides a therapeutic composition for pancreatitis which comprises a phosphoric diester compound of the following formula or a pharmacologically acceptable salt thereof ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represents hydrogen or methyl. The pharmaceutical composition of this invention can be used with advantage in the prevention and treatment of pancreatitis.

Therapeutic composition for pancreatitis

A liver protectant comprising a phosphoric diester compound of the following formula (wherein R.sub.1 and R.sub.2 are the same or different and each represents hydrogen or methyl) or a pharmacologically acceptable salt thereof. ##STR1## The liver protectant composition of this invention effectively inhibits the elevation of GOT and GPT, among other parameters, so that it is useful for the prevention and therapy , of acute liver disorder, chronic liver disorder and fuminant liver disorder. It can also be used in cirrhosis of the liver with success. The liver protectant composition of this invention can be used with advantage in liver damage associated with alcohol intake and hepatic impairment due to acetaminophen and other drugs. Furthermore, the liver protectant composition of this invention is of value in acute intrahepatic cholestasis.

Liver protectant tocophery-ascorbyl-phosphate

This invention relates to a lipid metabolism improving medicinal composition containing a phosphoric acid diester compound of the formula or a pharmacologically acceptable salt thereof. ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represents a hydrogen atom or a methyl group. The lipid metabolism improving medicinal composition of this invention lowers the plasma levels of triglycerides (TG), non-esterified fatty acids (NEFA), total cholesterol (T-ch), esterified cholesterol (E-ch), free cholesterol (F-ch), total lipid (TL) and lipid peroxides (LPO) and, among cholesterol fractions, increases the high-density lipoprotein (HDL) fraction and reduces the low-density ipoprotein (VLDL) fractions. Therefore, the composition can be used with advantage for the amelioration of hyperlipidemia associated with arteriosclerotic diseases such as myocardial infarction, angina pectoris, cerebral infarction, cerebral arteriosclerosis, etc., nephrosis, hypertension, diabetes, obesity and other diseases and for the prophylaxis of various cerebrovascular diseases.

Lipid metabolism improving medicinal composition

A pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis which comprise a phosphoric acid diester of the following formula: ##STR1## (wherein R.sub.1 and R.sub.2 are the same or different and each represents a hydrogen atom or a methyl group) or a pharmacologically acceptable salt thereof. Since the composition of this invention inhibits the formation of free radicals in the body, it can be advantageously used for the prophylaxis and treatment of various renal disorders such as glomerulonephritis, acute renal failure, uremia, adriamycin nephrosis, puromycin nephrosis, gentamicin- and cisplatin-induced disorders of the kidney, renal impairment due to paraquat and other agricultural chemicals, and immune complex nephritis. Moreover, the composition of this invention is also of use as a dialysis solution for extracorporeal hemodialysis with the propylactic/therapeutic effect on dialysis amyloidosis.

Growing community of inventors

Neyagawa, Japan

Rie Nagao